Precision medicine: From pharmacogenomics to pharmacoproteomics

Clinical Proteomics

Volumn 13, Issue 1, 2016, Pages

  Chambliss, Allison B ^a,b   Chan, Daniel W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarker; Pharmacogenomics; Precision medicine; Proteomics

Indexed keywords

CLOPIDOGREL; DASATINIB; EVEROLIMUS; FLUOROURACIL; OXALIPLATIN; PAZOPANIB; SIMVASTATIN; TAMOXIFEN;

DNA METHYLATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIATION; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHARMACOLOGY; PHARMACOPROTEOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT RESPONSE;

EID: 84992213777     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/s12014-016-9127-8     Document Type: Review

References (87)

1. Kaiser J. Senate panel approves $2 billion raise for NIH in 2016. Sci Mag. 2015. doi: 10.1126/science.aac6887.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-5.
3. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113:746-50.
4. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464-8.
5. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet. 2005;6:109-18.
6. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME. Pharmacogenomic discovery using cell-based models. Pharmacol Rev. 2009;61:413-29.
7. Penny MA, McHale D. Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am J Pharmacogenomics. 2005;5:53-62.
8. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics. 2012;13:55-70.
9. Niu N, Wang L. In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics. 2015;16:273-85.
10. Search Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008;359:789-99.
11. Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med. 2014;4:147-62.
12. Tardif JC, Rheaume E, Lemieux Perreault LP, Gregoire JC, Feroz Zada Y, Asselin G, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015;8:372-82.
13. Hu M, Tomlinson B. Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics. 2013;14:981-95.
14. Aslibekyan S, Straka RJ, Irvin MR, Claas SA, Arnett DK. Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Rev Cardiovasc Ther. 2013;11:355-64.
15. Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014;78:373-83.
16. Lin E, Lane HY. Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics. 2015;16:555-66.
17. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013;14:23-34.
18. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science. 2013;339:1563-6.
19. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187-93.
20. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007;13:3269-75.
21. Innocenti F, Schilsky RL, Ramirez J, Janisch L, Undevia S, House LK, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014;32:2328-34.
22. Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol. 2014;77:695-703.
23. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89:464-7.
24. Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guino E, Duran G, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13:209-17.
25. Cao S, Wang S, Ma H, Tang S, Sun C, Dai J, et al. Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy. Pharmacogenomics J. 2016;16:41-6.
26. Feinberg AP. The epigenetic basis of common human disease. Trans Am Clin Climatol Assoc. 2013;124:84-93.
27. Hunter P. The second coming of epigenetic drugs: a more strategic and broader research framework could boost the development of new drugs to modify epigenetic factors and gene expression. EMBO Rep. 2015;16:276-9.
28. Tang J, Xiong Y, Zhou HH, Chen XP. DNA methylation and personalized medicine. J Clin Pharm Ther. 2014;39:621-7.
29. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 2008;21:70-83.
30. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093-108.
31. Fisel P, Schaeffeler E, Schwab M. DNA methylation of ADME genes. Clin Pharmacol Ther. 2016;99:512-27.
32. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166(3):740-54. doi: 10.1016/j.cell.2016.06.017.
33. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, Roden DM. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genom. 2013;23:383-94.
34. Price MJ, Carson AR, Murray SS, Phillips T, Janel L, Tisch R, et al. First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the genotype information and functional testing (GIFT) exome study. J Am Coll Cardiol. 2012;59(13s1):E9. doi: 10.1016/S0735-1097(12)60010-2.
35. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546-53.
36. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343-50.
37. Vogel C, Abreu Rde S, Ko D, Le SY, Shapiro BA, Burns SC, et al. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol. 2010;6:400.
38. Ezkurdia I, Juan D, Rodriguez JM, Frankish A, Diekhans M, Harrow J, et al. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Hum Mol Genet. 2014;23:5866-78.
39. Jain KK. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics. 2004;5:331-6.
40. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57-63.
41. Haider S, Pal R. Integrated analysis of transcriptomic and proteomic data. Curr Genom. 2013;14(2):91-110.
42. Chapal N, Molina L, Molina F, Laplanche M, Pau B, Petit P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam Clin Pharmacol. 2004;18:413-22.
43. Witzmann FA, Grant RA. Pharmacoproteomics in drug development. Pharmacogenomics J. 2003;3:69-76.
44. Meister W. Pharmacogenomics/pharmacoproteomics Europe. Pharmacogenomics. 2002;3:449-52.
45. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51.
46. Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer. 2010;10:630-8.
47. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009;5:616-24.
48. Willems LI, Overkleeft HS, van Kasteren SI. Current developments in activity-based protein profiling. Bioconjug Chem. 2014;25:1181-91.
49. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteom. 2002;1:376-86.
50. Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A, et al. The quantitative proteome of a human cell line. Mol Syst Biol. 2011;7:549.
51. Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol. 2011;7:548.
52. Prieto DA, Johann DJ Jr, Wei BR, Ye X, Chan KC, Nissley DV, et al. Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. Biomark Med. 2014;8:269-86.
53. Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S, et al. Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteom. 2012;11:651-68.
54. Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov. 2006;5(4):310-20.
55. Ong SE, Schenone M, Margolin AA, Li X, Do K, Doud MK, et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009;106:4617-22.
56. Colzani M, Noberini R, Romanenghi M, Colella G, Pasi M, Fancelli D, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteom. 2014;13:1495-509.
57. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301-5.
58. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475:231-4.
59. Moellering RE, Cravatt BF. How chemoproteomics can enable drug discovery and development. Chem Biol. 2012;19:11-22.
60. Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest. 2015;125:4559-71.
61. Ning MM, Lopez M, Sarracino D, Cao J, Karchin M, McMullin D, et al. Pharmaco-proteomics opportunities for individualizing neurovascular treatment. Neurol Res. 2013;35:448-56.
62. Ohtsuki S, Hirayama M, Ito S, Uchida Y, Tachikawa M, Terasaki T. Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics. Expert Rev Proteom. 2014;11:303-13.
63. Wetmore BA, Merrick BA. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Pathol. 2004;32:619-42.
64. Rabilloud T, Lescuyer P. Proteomics in mechanistic toxicology: history, concepts, achievements, caveats, and potential. Proteomics. 2015;15:1051-74.
65. Van Summeren A, Renes J, van Delft JH, Kleinjans JC, Mariman EC. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol In Vitro. 2012;26:373-85.
66. Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics Research N. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014;95:154-67.
67. Hao D, Sarfaraz MO, Farshidfar F, Bebb DG, Lee CY, Card CM, et al. Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment. Metabolomics. 2016;12:58.
68. Miolo G, Muraro E, Caruso D, Crivellari D, Ash A, Scalone S, et al. Phamacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016.
69. National Cancer Institute Clinical Proteomic Tumor Analysis Consortium. http://proteomics.cancer.gov/programs/cptacnetwork. Accessed 29 July 2016.
70. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55-62.
71. Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166:755-65.
72. Pharmacogenomics Research Network. http://www.pgrn.org. Accessed 29 July 2016.
73. Pharmacometabolomics Research Network. https://pharmacometabolomics.duhs.duke.edu/home. Accessed 29 July 2016.
74. Neavin D, Kaddurah-Daouk R, Weinshilboum R. Pharmacometabolomics informs pharmacogenomics. Metabolomics. 2016;12:121.
75. Kaddurah-Daouk R, Weinshilboum R, Pharmacometabolomics Research Network. Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin Pharmacol Ther. 2015;98:71-5.
76. U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (2016). Accessed 29 July 2016.
77. Tutton R. Pharmacogenomic biomarkers in drug labels: what do they tell us? Pharmacogenomics. 2014;15:297-304.
78. U.S. Food and Drug Administration. Nucleic acid based tests. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm. Accessed 29 July 2016.
79. Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: Framework for regulatory oversight of laboratory developed tests (LDTs). U.S. Department of Health and Human Services Food and Drug Administration, Docket no. FDA-2011-D-0360; 2014.
80. Levy KD, Pratt VM, Skaar TC, Vance GH, Flockhart DA. FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. J Clin Pharmacol. 2015;55:725-7.
81. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteom. 2013;10:13.
82. Tabb DL, Vega-Montoto L, Rudnick PA, Variyath AM, Ham AL, Bunk DM, et al. Repeatability and reproducibility in proteomic identifications by liquid chromatography - tandem mass spectrometry. J Proteome Res. 2010;9(2):761.
83. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27:633-41.
84. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18:1509-17.
85. NIH Cancer Genome Atlas. http://cancergenome.nih.gov. Accessed 8 Sept 2016.
86. The International Cancer Genome Consortium. http://www.icgc.org. Accessed 8 Sept 2016.
87. Ferreira CR, Yannell KE, Jarmusch AK, Pirro V, Ouyang Z, Cooks RG. Ambient ionization mass spectrometry for point-of-care diagnostics and other clinical measurements. Clin Chem. 2016;62:99-110.